DOSING &
LAB MONITORING
ONE PILL. ONCE-DAILY.
IR=intolerance or inadequate response;
TNFi=tumor necrosis factor inhibitor
RINVOQ is a once-daily pill that comes in three dosage strengths
One strength for induction and two strengths for maintenance
INDUCTION
The recommended induction dose of RINVOQ is 45 mg QD for 8 weeks.
MAINTENANCE
The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily.
A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease.
Discontinue if an adequate therapeutic response is not achieved with the 30 mg dose.
Use the lowest effective dose needed to maintain response.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and cyclosporine.
Administration1
- Instruct patients to take one pill, once daily.1
- Ensure pill is taken whole. Do not chew, crush, or split.1
- RINVOQ can be taken with or without food. Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ.1
- Instruct patients to notify their healthcare provider if they repeatedly notice intact RINVOQ tablet or fragments in stool or ostomy output.
Lab monitoring and dosing considerations1
Perform lab testing for:
INTERRUPT IF PATIENT DEVELOPS A SERIOUS OR OPPORTUNISTIC INFECTION.
*Treatment can be initiated or restarted after levels return above specified values, drug-induced liver injury diagnosis is excluded, or infection is controlled.1
Interested to learn about safety data for RINVOQ?
See RINVOQ’s safety data across clinical trials
